Semaglutide-Glycine-Cyanocobalamin Injectable — Class II drug recall D-0471-2026
Ongoing recall by PAYLESS COMPOUNDERS, LLC, reported 2026-04-22, distributed in OR. Lack of Assurance of Sterility
| Recall number | D-0471-2026 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | PAYLESS COMPOUNDERS, LLC, Beaverton, OR, United States |
| Recall initiated | 2026-03-06 |
| Classified | 2026-04-13 |
| Reported by FDA | 2026-04-22 |
| Distributed | OR |
| Quantity | 91 vials |
| Reason classes | sterility |
Product
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
Reason for recall
Lack of Assurance of Sterility
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0471-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.